Key Details
Price
$6.50Annual ROE
-2.97%Beta
2.27Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 05, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB) announced today that it has been named “Overall BioTech Company of the Year” in the fourth annual BioTech Breakthrough Awards program.
Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.01 per share a year ago.
FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure.
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Operator Thank you for standing by. My name is Luella, and I will be your conference operator today.
Cytek has developed a revolutionary tool to automate panel design. SpectroPanel is an intelligent algorithm that suggests optimized panels in minutes.
FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, officially announced its Enhanced Small Particle (ESP™) Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems.
Cytek Biosciences, Inc. (Nasdaq: CTKB), a prominent company in cell analysis solutions, is dedicated to advancing the cell analysis market through participation in important industry events globally.
Investors frequently consider the advice of Wall Street analysts before making decisions on whether to buy, sell, or hold a stock. Changes in ratings by these analysts, who are employed by brokerage firms, can impact the price of a stock based on media reports.
The intense selling pressure on Cytek Biosciences (CTKB) appears to have eased as it is now considered oversold from a technical standpoint. Furthermore, the consensus among Wall Street analysts in raising earnings forecasts suggests that the stock may be poised for a turnaround.
The average price target suggests a potential 47.6% increase for Cytek Biosciences (CTKB). Although studies show this metric may not always be accurate, a rise in earnings forecasts could indicate a positive outlook for the stock in the short term.
FAQ
- What is the primary business of Cytek Biosciences?
- What is the ticker symbol for Cytek Biosciences?
- Does Cytek Biosciences pay dividends?
- What sector is Cytek Biosciences in?
- What industry is Cytek Biosciences in?
- What country is Cytek Biosciences based in?
- When did Cytek Biosciences go public?
- Is Cytek Biosciences in the S&P 500?
- Is Cytek Biosciences in the NASDAQ 100?
- Is Cytek Biosciences in the Dow Jones?
- When was Cytek Biosciences's last earnings report?
- When does Cytek Biosciences report earnings?
- Should I buy Cytek Biosciences stock now?